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Abstract
Background: This study aimed to profile levels of blood cells and serum cytokines during afebrile and febrile
phases of periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome to advance
pathophysiological understanding of this pediatric disease.
Methods: A cohort of patients with a median age of 4.9 years experiencing ‘typical PFAPA’ episodes participated
in this study. Blood cells and serum cytokines were analyzed by CBC analysis and multiplex ELISA.
Results: Oscillations in the concentration of blood cells during the afebrile and febrile phases of typical PFAPA
syndrome were observed; novel findings include increased monocytes and decreased eosinophils during a febrile
episode and increased thrombocytes in the afebrile interval. Relatively modest levels of pro-inflammatory cytokines
were present in sera. IFNg-induced cytokine IP10/CXCL10 was increased after the onset of fever while T cell-
associated cytokines IL7 and IL17 were suppressed during afebrile and febrile periods.
Conclusions: Identification of dysregulated blood cells and serum cytokines is an initial step towards the
identification of biomarkers of PFAPA disease and/or players in disease pathogenesis. Future investigations are
required to conclusively discern which mediators are associated specifically with PFAPA syndrome.
Background
The periodic fever, aphthous stomatitis, pharyngitis and
cervical adenitis (PFAPA) syndrome was originally
described by Marshall et al in 1987 and the acronym,
PFAPA, was coined two years later together with the
diagnostic criteria [1,2]. PFAPA syndrome is regarded as
a non-hereditary disease of unknown etiology although
the clinical observation is that, in a small proportion of
cases, one of the parents or a more distant relative had
similar symptoms in childhood [3]. The actual incidence
of PFAPA syndrome in the pediatric population is not
known but it is more common than the hereditary peri-
odic fevers, except in populations with an ethnic origin
in the Eastern Mediterranean basin where FMF is more
common. Every pediatrician is likely to encounter at
least one case of PFAPA during his or her career [4].
Autoinflammatory attacks in PFAPA syndrome occur
within a 2-8 week interval with remarkable clockwork
periodicity in approximately 50% of patients [3,5,6]. As
in other periodic fever syndromes, there is a marked
increase in CRP, SAA, ESR and leukocyte concentration
[6-8], which are indicative of a prominent, acute inflam-
matory reaction. In PFAPA, these indicators return to
normal levels, symptoms subside and patients resume
daily activities between episodes [9]. Although the epi-
sodes are self-limiting in PFAPA without any known,
increased risk of sequel or mortality, the recurrent epi-
sodes have a major impact on the daily life of the entire
family. Treatment options aim to reduce febrile symp-
toms and typically include NSAIDs and paracetamol [5].
Steroid treatment will most often abort an episode
within hours, yet tends to reduce the length of the
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correlated with the resolution of the disease in a major-
ity of cases [11-14]. Irrespective of treatment options, an
inevitable cessation of the steadfast periodicity of attacks
will occur on average 4.5 years after the first attack [5].
The spontaneous remission of the syndrome is indepen-
dent of antibiotic, anti-inflammatory, or immunosup-
pressive treatment [5,15]. Our experience however, is
that a considerable proportion of patients continue to
have episodes for several years after their “recovery”.
These episodes are often mild and not always reported.
At present, the diagnosis of PFAPA is made on the
basis of clinical phenotype, detailed case history and an
exclusion of other diseases, including, infections, immu-
nodeficiencies, autoimmune diseases and monogenic
periodic fevers. Five clinical criteria must be fulfilled in
order to diagnose PFAPA syndrome ([5]; see also Sub-
jects and Methods). Additional, discriminatory features
that may aid in the differential diagnosis of PFAPA
include the duration and remarkable clockwork periodi-
city of inflammatory attacks. Episodes typically last 4-5
days in PFAPA, which is similar to HIDS (3-6 days),
longer than FMF (6 hours-3 days) and shorter than
TRAPS (>7 days) [2,5,6,8,15,16]. The prompt resolution
of an episode in response to corticosteroids is another
typical feature of PFAPA that is often considered when
reaching a diagnosis [5,10].
To further advance the pathophysiological understand-
ing of the disease, experimental investigations at the cel-
lular and molecular level are required. This study was
designed with the intended purpose to profile blood cell
and serum cytokine levels during both afebrile and feb-
rile phases of PFAPA syndrome.
Subjects and Methods
Participants
Ten children with diagnosed PFAPA were selected to
participate in this study based on age, ethnicity and clin-
ical presentation. Participants 1) were less than 7 yr. of
age, 2) fulfilled the standard clinical criteria for PFAPA
syndrome [5], namely i) consistent recurring fevers from
an early (<5 years) age, ii) symptoms in the absence of
upper respiratory tract infection with at least one of the
following clinical signs: aphthous stomatitis, cervical
lymphadenitis or pharyngitis, iii) exclusion of cyclic neu-
tropenia, iv) asymptomatic clinical phenotype between
febrile episodes, and v) normal growth and development,
3) had febrile episodes lasting 3-5 days followed by 4) an
asymptomatic interval between attacks (on average, 3-5
weeks) and 5) lacked additional features that would sug-
gest a hereditary periodic fever syndrome: skin rash,
arthritis, severe abdominal pain, diarrhea, thoracic pain
and splenomegaly, fever episodes longer than 7 days, a
history of hearing loss or symptoms secondary to cold
exposure [6,17]. Moreover, patients with an ethnic ori-
gin in the Eastern Mediterranean basin, the Netherlands,
Belgium or France were excluded to further minimize
the risk of including patients with hereditary FMF or
MKD. To our knowledge MKD has never been geneti-
cally diagnosed in a population of Swedish ethnic origin.
Children received clinical care at the Queen Silvia Chil-
dren’s Hospital (Gothenburg, Sweden) or Uddevalla
C o u n t yH o s p i t a l ,( U d d e v a l l a ,S w e d e n ) .I ft h e r ew a sa n y
doubt that fever on the day of sampling was not caused
by a PFAPA episode, a pediatrician in the field assessed
the patient; otherwise patients were not routinely
assessed at the time of sampling. The patients did not
receive steroids or prophylactic treatment during febrile
episodes or afebrile intervals either during the study or
immediately preceding their participation in the study.
Controls were recruited among children that were
admitted to either hospital for minor surgery. Approval
for the study was obtained from the Regional Ethical
Review Board at the University of Gothenburg, Sweden.
Informed consent from the parents of patients and con-
trols was obtained in accordance with the Declaration of
Helsinki.
Samples
15 ml of blood from patients and controls were col-
lected in Vacutainer® tubes containing heparin or EDTA
or, for the isolation of sera, clot activators (Becton Dick-
inson). Blood was collected from patients after the com-
mencement of fever (febrile sample) and a minimum of
7 days after the termination of fever (afebrile sample).
With the exception of two patients, blood was collected
from all febrile patients within 24 hours of fever onset.
For the two outstanding patients, blood was collected
from one patient (P04) 120 hours after fever began
while the other patient (P03) developed fever 12 hours
after the blood was collected. Sera were obtained by
centrifugation of blood at 1200-1500 revolutions per
minute (rpm) for 10 minutes (mins). For cytokine deter-
minations (see below), sera were stored in sterile tubes
at -80°C prior to analysis.
Complete blood cell count and acute phase reactant levels
A complete blood cell count (CBC) and white blood cell
(WBC) differential was determined using an ADVIA
Cell counter. Acute phase proteins (CRP and SAA) and
procalcitonin were measured by ELISA (Clinical Immu-
nology Laboratory, Sahlgrenska University Hospital,
Gothenburg).
Isolation and culture of human peripheral blood
mononuclear cells (PBMC)
PBMC from patients and controls were prepared as pre-
viously described [18]. In brief, whole blood was sepa-
rated by centrifugation over Ficoll at 1000 rpm, 30 mins
at 4°C. PBMC were isolated from the buffy layer, washed
and suspended in cold PBS. PBMC were seeded at 1 ×
Brown et al. BMC Pediatrics 2010, 10:65
http://www.biomedcentral.com/1471-2431/10/65
Page 2 of 1010
6 cells/ml in 96-well V-bottom plates (2.5 × 10
5 cells/
well; Brandtech Scientific Inc) and incubated 24 hours
at 37°C, 5% CO2 in RPMI-1640 medium supplemented
with 10% heat-inactivated FCS, 2 mM L-glutamine, 1
mM sodium pyruvate and 50 Units/ml PEST (PAA
Laboratories). Plates were centrifuged at 1000 rpm, 5
mins to pellet cells after which supernatants were trans-
ferred to sterile 96-well plates and stored at -80°C until
analysis.
Detection of inflammatory mediators
Inflammatory mediators were analyzed in a subset of
serum samples and supernatants using a 25-Plex inflam-
matory cytokine kit (Biosource International Inc) [19]
and Luminex 100™ StarStation software (Applied Cyto-
metry Systems) as described [18]. To minimize variabil-
ity in cytokine levels due to the time of sampling, three
febrile samples acquired at a similar time after the onset
of fever (~15 hr.) were selected for multiplex analysis.
An IP10 cytokine bead array assay (BD Biosciences) was
used according to manufacturer’s protocols to confirm
multiplex results on a larger sample set.
Statistical Analysis
Statistical evaluation of data was performed by non-para-
metric one-way ANOVA with post-hoc analysis
(Tukey’s). A p-value < 0.05 was considered statistically
significant; * indicates p <0 . 0 5 ,* *p <0 . 0 1a n d* * *p <
0.001. Medians are indicated by horizontal lines in the
figures. Mean fold change ± SEM are reported in the text.
Results
Participants have “typical PFAPA” syndrome
Children diagnosed with PFAPA syndrome according to the
standard clinical criteria [5] were included in this study.
They were assessed by a pediatrician experienced in the
field and were described as having “typical PFAPA”. This
designation was based primarily on clinical grounds;
patients had recurring fever for, on average, 4 days with a
history of regular intervals between febrile episodes and
symptoms consistent with the acronym for PFAPA. More-
over patients lacked symptoms of, and ethnic predisposition
to, hereditary fevers (see Subjects and Methods for details).
The median age of the patients was 4.9 years, ranging from
11 months to 6.8 years. Beyond this age, febrile flares often
occur with less frequency and intensity and, in almost all
cases, eventually cease altogether [5]. Controls were
recruited from otherwise healthy children that were
admitted to hospital for minor surgery. The median age of
this group was 5.2 years, ranging from 19 months to 9.5
years. Characteristics of patients and controls are described
in Table 1 (patients) and Additional File 1, Table S1.
Acute phase proteins CRP and SAA are elevated
Serum concentrations of C-reactive protein (CRP) and
serum amyloid A (SAA) were substantially elevated in
patients with fever (Table 2 and Additional File 2, Figure
S1) which is typical for the syndrome. Worthy of note
are the elevated levels of SAA in some afebrile PFAPA
samples, suggesting that SAA is an extremely sensitive
inflammatory marker. It has been suggested that procal-
citonin may be used to distinguish fever that arises from
PFAPA from fever associated with a bacterial infection,
the latter of which would correlate with procalcitonin
concentrations above 0.2 μg/L (http://www.kliniskkemi.
se and [20]). Accordingly, procalcitonin levels in sera
from afebrile patients (AFP), febrile patients (FP) and
controls were less than this reference concentration
(Table 2 and Additional File 2, Figure S1). Even at these
low concentrations there was a significant difference in
procalcitonin levels between FP sera and AFP/control
sera. Lastly, all participants were free from overt signs of
infection at the time of sampling and serum levels of
endotoxin were similar in AFP, FP and controls (data
not shown), providing additional evidence that PFAPA
syndrome was the cause of fever in our cohort.
The abundance of thrombocytes, neutrophils, monocytes,
lymphocytes and eosinophils undulate within a PFAPA
cycle
The concentration of RBC, thrombocytes, WBC and
constituent WBC subtypes (monocytes, lymphocytes,
neutrophils, basophils and eosinophils) were evaluated
in blood drawn from controls and patients. Data are
presented in Figure 1, Figure 2 and Additional File 3,
Table S2. The concentrations of both RBC and WBC in
AFP samples were comparable to that in controls. The
absolute numbers of thrombocytes in AFP blood how-
ever exceeded the upper limit of the normal range and
were 1.5 ± 0.1 fold higher than thrombocytes in blood
from FP and controls.
In FP blood, the absolute numbers of leukocytes was
elevated (1.5 ± 0.2 fold) compared to the absolute num-
bers of leukocytes in control samples (Figure 2 and
Additional File 3, Table S2). Thus, FP blood exhibited
mild leukocytosis in contrast to controls but, by defini-
tion, clinical leukocytosis is not a defining characteristic
of the febrile episodes. Two notable exceptions were
febrile patients P05 and P06 that did not have elevated
WBC at the time of sampling even though the febrile
episode was consistent with previous febrile attacks and
CRP and SAA levels were elevated. The increase in FP
leukocytes corresponded with an increased absolute
neutrophil count (ANC) and absolute monocyte count
(AMC), which were elevated 2.6 ± 0.4 and 1.8 ± 0.1
fold, respectively, over concentrations in control blood.
It is important to note that while the elevated ANC and
AMC in FP blood were statistically distinguishable from
controls, they nevertheless fell within normal ranges
(Additional File 3, Table S2). While absolute lymphocyte
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range, there was a substantial decrease in ALC in FP
blood (65% less) compared to AFP samples. CBC analy-
sis also revealed a major, unexpected difference in abso-
lute eosinophil count (AEC) with less eosinophils in
each of the FP samples (89% less) than in AFP samples.
Classic pro-inflammatory cytokines TNFa and IL1b are not
elevated in febrile sera
A multiplex bead ELISA was used to determine the con-
centration of classic pro-inflammatory cytokines TNFa,
IL1b and IL6 in FP sera that was drawn at approxi-
mately the same time after the onset of fever (~15
hours, n = 3). IL-6 was significantly increased in FP sera
compared to control sera. The levels of TNFa and IL1b
in all samples approached the lower limits of detection
in the multiplex assay. Nevertheless, TNFa and IL1b
concentrations were similar or slightly repressed in FP
sera compared to control sera (Figure 3 and Additional
File 4, Table S3). Given that the expression of IL-6 is
often induced by TNFa or IL1b [21] and these cytokines
were found in PFAPA sera 4 hours after the onset of
fever [22], we anticipate that TNFa and IL1b peak early
in the fever period then quickly approach homeostatic
levels. A rapid oscillation of TNFa and IL1b in vivo
occurs in response to infection [23,24].
Th2- and Th17-associated cytokines are suppressed
The presence of other pro-inflammatory cytokines was
also investigated in sera by multiplex ELISA. The lym-
phocyte-specific cytokine, IL7, and CD4
+ T-helper cyto-
kine, IL17, were suppressed in both AFP and FP sera
compared to controls (Figure 4A and Additional File 4,
T a b l eS 3 ) .I L 1 7i sp r o d u c e dp r i m a r i l yb yas u b s e to f
CD4
+ T-helper-17 (Th17) cells. The activation of parti-
cular lymphocyte subsets, namely Th1, Th2 and Th17,
is evident by the presence of particular cytokines that
simultaneously drive one Th response while repressing
others. The prototypic Th2 cytokine IL4 was present at
comparable concentrations in AFP, FP and control sera.
Concentrations of IL13, a Th2-associated cytokine, and
CCL11/Eotaxin, a Th2-associated chemokine, were sup-
p r e s s e di ns e r af r o mF Pc o m p a r e dt oc o n t r o l s( I L 1 3 )
and AFP (IL13 and CCL11) sera (Figure 4B and Addi-
tional File 4, Table S3). The lower concentrations of
these serum cytokines and IL17 suggested that neither a
Th17- nor a Th2-type inflammatory response were
active in FP sera.
Th1-associated chemokine IP10 is elevated
The expression of the classic Th1-associated cytokines
IFNg and IL12 were not elevated in sera from AFP, FP
and controls. The concentrations however of the IFNg-
Table 1 Clinical description of PFAPA patients
aID Gender
(F/M)
Allergy
(+/-)
bLength of
episode (d)
cInterval
between
episodes (wk)
dPFAPA
characteristics
Other signs or
symptoms during
episodes
eAge (yr;mo) at
fFebrile
sample
(h)
A
(+/-)
P
(+/-)
CA
(+/-)
onset diagnosis sampling
(AF/F)
P01 F - 3-5 3-5 + + + Occasional vomiting 0;2 0;11 0;11
P02 M - 4-5 3-4 + + + 0;8 1;5 1;8
P03 F - 3-4 4 + + + Leg pain 2;3 3;6 3;8 -12
P04 M + 3-4 3-4 + + + 4;5 5;1 5;2/5;2 120
P05 M - 3-4 4-5 - + + 3;4 4;2 4;2/4;2 15-17
P06 F - 5 4-6 + + + 1;9 5;4 6;9/6;10 13-15
P07 M - 4 4 + + + Sporadic abdominal
pain
1;6 3;10 5;6/5;5 15-18
P08 F - 3 4 + + - Frequent abdominal
pain
1;6 4;8 5;3/5;2 15
P09 M - 4-5 2-3 + + + Sporadic abdominal
pain & arthralgia
1;7 4;7 4;7 15-17
P10 F + 4 3-4 + + + Sporadic vomiting &
abdominal pain
2;1 4;11 6;0 12-17
aEach individual was given an identification number (ID) where the numerical digit is unique to each individual.
bDuration of episodes as reported by the parents in days (d)
cInterval between episodes (from first to first day in successive episodes) as reported by the parents in weeks (wk)
dSymptoms of PFAPA according to the acronyms, A; Aphthous stomatitis, P; Pharyngitis, CA; Cervical adenitis
eAge at onset as reported by the parents. Age at diagnosis was collected from medical records. Age at in the AF: Afebrile or F: Febrile period. Age reportedi n
years (yr) and months (mo).
fThe number of hours (h) that the patient had fever before samples were taken
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were elevated, albeit to varying degrees, in sera from FP
(Figure 4C and Additional File 4, Table S3). An inde-
pendent bead-based ELISA specific for IP10 was used to
validate the elevated concentration of IP10 in FP sam-
ples (AFP n = 8, FP n = 8, controls n = 13). The results
revealed that IP10 was indeed elevated (p <0 . 0 0 1 )i n
sera taken ~15 hours and even as late as 120 hours after
the onset of fever. Elevated levels of the IFNg-induced
chemokines CXCL9/MIG and CXCL10/IP10 in the
absence of Th2- and Th17-associated cytokines indi-
cated that components of a Th1-type inflammatory
response coincide with fever in PFAPA syndrome.
PBMC are not intrinsically activated in PFAPA
Since the AMC was elevated in FP blood and monocytes
produce, among others, IL6, CXCL9/MIG and CXCL10/
IP10, we questioned if cytokine production by isolated
PBMC could reflect the cytokine profiles observed in
sera. This approach has been used to prove that blood
cells from individuals with HIDS, a monogenic periodic
fever syndrome, and CGD, a condition in which sterile
inflammatory disorders develop, are inherently active
[25,26]. PBMC from AFP, FP and controls were cultured
ex vivo for 24 hours following which the cell superna-
tants were evaluated by multiplex ELISA for the sponta-
neous secretion of the same pro-inflammatory cytokines
that were evaluated in sera. No significant differences in
cytokine levels were detected between control and
patient samples for any of the inflammatory cytokines
analyzed (data not shown). Viability and responsiveness
of PBMC was confirmed by an increase in cytokine pro-
duction in response to LPS or PMA/ionomycin (data
not shown). Thus the altered levels of inflammatory
mediators in sera from AFP and FP compared to con-
trols are either produced independently of PBMC or
depend on in vivo regulatory factors.
Discussion
Periodic fevers are a group of disorders that belong to the
recently established and growing family of autoinflamma-
tory diseases. Periodic fevers are characterized by see-
mingly unprovoked, recurrent attacks of fever and severe
inflammation in the absence of infectious or autoimmune
etiology. The onset of disease is generally noted during
childhood or, less frequently, adolescence (reviewed by
[8,27-29]). Over the past two decades, advances in both
the clinic and the laboratory have accelerated our under-
standing of autoinflammation. Within a five-year period
(1997-2002), the genetic bases were discovered for each
of the hereditary, monogenic periodic fevers (TRAPS,
F M F ,H I D S ,C I N C A ,M W S ,F C A S )t h a tw e r et h ef o u n d -
ing members of the autoinflammatory family. All of these
diseases except TRAPS show increased secretion of IL1b
due to heightened activity of the NLR family member
NLRP3 (NALP3/cryopyrin; [3]). The autoinflammatory
family now includes an increasing number of complex,
polygenic/multifactorial diseases (including PFAPA, adult
onset Still’s disease, chronic recurrent multifocal osteo-
myelitis, Behçet’sa n dC r o h n ’s disease) that are of
unknown etiology.
An overlap in clinical characteristics exists within the
autoinflammatory family itself and to some degree with
Table 2 Acute phase proteins in serum
eCRP
fSAA
gProcalcitonin
dID mg/L mg/L μg/L
C01 <5 <11 0.06
C02 0.0 <11 0.05
C03 0.3 <11 0.10
C04 0.2 <11 0.06
C05 0.1 <11 0.07
C06 0.1 20 0.16
acontrol C07 0.2 <11 <0.05
C08 0.4 53 0.09
C09 1.9 <11 0.12
C10 1.0 14 0.06
C11 0.4 <11 <0.02
C12 3.5 28 0.06
C13 0.6 <11 0.09
C14 0.5 <11 0.06
P01 <5 15 0.06
P02 3.3 13 0.04
P03 1.2 16 0.10
bafebrile P04 10.7 26 0.14
(AF) P05 1.0 <11 0.05
P06 0.5 <11 0.05
P07 3.3 59 0.03
P08 0.5 12 <0.05
P05 >75 >600 0.21
P06 >75 560 0.12
P07 >75 560 0.08
cfebrile P08 44 >600 0.10
(F) P09 67 >600 0.14
P10 75 >600 0.10
P03 1.22 11 0.09
P04 >75 590 0.41
Data shown as scatter plots in Additional File 2, Figure S1
a-dConcentration of acute phase proteins in sera from
ahealthy children and
PFAPA children in either an
bafebrile interval or
cwithin the first 20 hours of a
febrile episode. Samples from FP03 and FP04 were drawn respectively ࿄ 12
hours before and ࿄120 hours after fever appeared. Numerical digits in the
assigned
didentification number (ID) are unique to individuals. Values in bold
are outside the range for healthy children http://www.kliniskkemi.se.
eCRP; C reactive protein. Upper limit of detection is 75 mg/L. Concentration in
healthy children is <5 mg/L.
fSAA; serum amyloid A. Lower and upper limits of detection are 11 and 600
mg/L. Concentration in healthy children is <11 mg/L.
gIn the absence of a bacterial infection, the concentration of procalcitonin is
<0.2 μg/L.
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recurrent infections. In this setting, the demarcation and
diagnosis of specific autoinflammatory diseases can be a
difficult task. The PFAPA criteria do not exclude other
periodic fever syndromes [6]. Furthermore, disease entities
based on criteria, like the PFAPA syndrome, might conceal
different diseases from a pathophysiological perspective. In
the absence of definitive markers of disease, the differential
diagnosis of PFAPA syndrome can be cumbersome and
sometimes uncertain. Genetic analyses for hereditary peri-
odic fever syndrome are expensive and inaccessible in
many contexts. Our experience is that genetic analyses are
of limited value in patients with a typical PFAPA syn-
drome without additional features that suggest a heredi-
tary periodic fever syndrome; an opinion shared by others
[10]. In an attempt to reveal clues about the pathogenic
mechanism(s) or biomarkers of this uncommon pediatric
disease, we monitored the concentration of blood cells
and serum cytokines in children with “typical PFAPA”
during the asymptomatic and febrile intervals of their dis-
ease. The median age of children in this study was 4.9
years. Children in this age range are the most likely to
experience ‘typical PFAPA’ episodes. This is an important
and distinguishing feature of our study since PFAPA epi-
sodes may differ in older children that are expected to
have waning disease or have ‘grown out’ of their episodes.
We recognize that by selecting a well-defined group of
patients, our cohort is relatively small thus we encourage
independent confirmation of the results presented herein.
Fever in our cohort of patients was associated with an
increased WBC count, due to an increase in ANC and
AMC, but not ALC. We also find evidence for decreased
Figure 1 Red blood cells and thrombocytes. Red blood cells (RBC; measured as g/L of hemoglobin (Hb), left) and thrombocytes (x 10
9/L,
right) in blood from controls (n = 14), afebrile patients (n = 7-8) and patients with fever 12-18 hours (febrile, n = 6) were enumerated. Absolute
cell numbers are reported in Additional File 3, Table S2.
Figure 2 Scatter plot of white blood cells. The abundance (x 10
9/L) of white blood cells (WBC; top left), lymphocytes (top centre), monocytes
(top right), neutrophils (bottom left), eosinophils (bottom centre) and basophils (bottom right). Absolute cell numbers are reported in Additional
File 3, Table S2.
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cytes in the afebrile interval. While the severely depreciated
levels of eosinophils may be unique to PFAPA and needs
further investigation, thrombocytosis may be a delayed,
acute phase reaction to the previous febrile episode. It will
be important to discern such differences as well as any
functional changes that may correlate with alterations in
cell abundance. It is also important to note that many of
the observed changes in blood cell densities may be missed
on a CBC analysis of blood from individual PFAPA
patients due to the substantially wide range of ‘normal’
blood cell concentrations for children. Whether absolute
cell counts that fall in the normal range but are signifi-
cantly different between healthy and PFAPA children carry
any biological significance remains to be proven.
The classic pro-inflammatory cytokines TNFa and
IL1b are typically associated with an inflammatory
response and play cardinal pathogenic roles in mono-
genic, hereditary periodic fevers [30]. In contrast, we did
not find elevated levels of TNFa or IL1b in FP sera ~15
hours after the onset of fever. In response to ex vivo sti-
mulation with LPS, PBMC from febrile patients pro-
duced more TNFa and IL1b compared to control and
afebrile PBMC over a 24 hr period (data not shown). It
is therefore plausible that TNFa or IL1b appeared ele-
vated in FP sera early after the onset of fever. A similar
assumption may be applicable to IFNg since the IFNg-
inducible cytokine IP10, but not IFNg itself, was present
at elevated levels in FP sera. It is of course possible that
other mechanisms for IP10 regulation are at play. We
however predict that cytokines TNFa,I L 1 b and IFNg
rise and fall rapidly in the early hours of fever while the
concentration of other cytokines (IL6 and IP10) are
enhanced later in the fever period and return to control
levels during the afebrile interval. The oscillations of
these cytokines (TNFa,I L 1 b,I F N g, IL6 and IP10) in
conjunction with the diminished levels of IL4 and IL17
are indicative of a typical, IFNg-dependent (Th1) inflam-
matory response (also reported by [22]).
It has been suggested that like the periodicity of
inflammatory attacks in PFAPA, cytokine-producing
cells in these patients may also display unique bior-
hythms [31]. While AMC cycled both with febrile peri-
ods and the in vivo expression of monokines IL6 and
IP10, there was no correlation between increased AMC
in FP blood and the production of cytokines by mono-
cytes (PBMC) cultured ex vivo. These data suggested
that PBMC in PFAPA syndrome, unlike HIDS [25] are
not intrinsically activated cells and may depend on in
vivo regulatory factors. Alternatively, cell types other
than PBMC, including neutrophils, eosinophils, epithe-
lial and endothelial cells, may be responsible for the reg-
ulation of cytokines, or other mediators, in PFAPA
syndrome. Gut epithelial cells for example, are central
to the pathogenesis of Crohn’s disease due to dysregu-
lated NLR signaling.
The panel of proinflammatory cytokines investigated
in FP sera were present at relatively moderate levels and
cycled in a manner that seemed consistent with general-
ized fever and a typical Th1-type inflammatory response,
i.e., the cytokine profiles may not be unique to febrile
episodes experienced by PFAPA patients. Future investi-
gations require additional controls from children with
other periodic fevers and acute infections. The early
stages of a fever period are coincident with dynamic
cytokine regulation where small variations in sampling
time can yield remarkably different results. Due to tech-
nical and ethical restrictions associated with sampling at
multiple time points after the onset of fever, it may be
advisable to investigate cytokine profiles of disease [32]
during the afebrile interval. While clinically asympto-
matic, we, and others [22] demonstrate fluctuations in
cytokines in the afebrile phase suggesting that the dis-
ease is active at the cellular level also between febrile
flares. This is supported further by the observation of
elevated levels of SAA in some patients during the afeb-
rile period and in accordance with another study in
which SAA levels fluctuated in patients with FMF that
Figure 3 Classic pro-inflammatory cytokines. The concentrations (pg/ml) of prototypic pro-inflammatory cytokines TNFa (left), IL1b (centre)
and IL6 (right) in sera from controls (n = 3), afebrile patients (n = 3) and febrile patients ~15 hours after the onset of fever (n = 3) were
measured using a multiplex bead ELISA. The lower limits for detection of IL1b and IL6 are indicated by a dotted line. Measured quantities are
reported in Additional File 4, Table S3.
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died concluded that the fluctuations were due to subcli-
nical inflammatory activity [33]. The reduced
concentrations of, for example IL7, IL17 and IFNg that
were observed in the afebrile interval may lay the foun-
dation for future investigation into (defective) T cell reg-
ulation in PFAPA syndrome. Moreover, there is a need
for investigations into the regulation and role of SAA in
subclinical infection and inflammation.
Conclusions
Herein we report oscillations in the concentration of
blood cells during the afebrile and febrile phases of typi-
cal PFAPA syndrome. An increase in circulating
monocytes and thrombocytes and a major decline in cir-
culating eosinophils are novel findings. Further, we find
a relatively modest level of pro-inflammatory cytokines
in the sera ~15 hours after the onset of fever with a ten-
dency towards an IFNg-driven inflammatory response
and suppressed levels of T cell-associated cytokines dur-
ing the afebrile interval. Cytokine and blood cell oscilla-
tions in PFAPA syndrome are illustrated Figure 5.
Future investigations are required to conclusively dis-
cern which cells and cytokines are associated with
inflammation (fever) in general and which are specific to
febrile episodes in PFAPA syndrome. Advances of this
nature at the cellular and molecular level will facilitate
the identification of biomarkers of disease or players in
disease pathogenesis.
Additional material
Additional file 1: Table S1: Clinical description of control children.A
table listing age, gender, allergy and reason for hospital admission of
healthy children enrolled as controls in this study.
Additional file 2: Figure S1: Acute phase serum proteins. The
concentration of acute phase C-reactive protein (CRP, mg/L, left), serum
amyloid A (SAA, mg/L, centre) and procalcitonin (μg/L, right) in sera from
controls (n = 14), afebrile patients (n = 8) and patients with fever 12-18
hours (febrile, n = 6). Values are reported in Table 2. A dotted line
indicates the upper and lower limits for detection for CRP and SAA or
the lowest concentration of procalcitonin that may indicate an infection.
Figure 4 T-helper-associated cytokines and chemokines.T h e
concentration (pg/ml) of (A) lymphocyte activator IL7 (left), Th17-
associated cytokine IL17 (right) (B) Th2-associated cytokine IL4 and
chemokine CCL11/Eotaxin (left and right respectively) and (C) Th1-
associated cytokines and chemokines IFNg (top left), MIG/CXCL9
(top right), and IP10/CXCL10 (bottom left) were measured in sera
from controls (n = 3), afebrile patients (n = 3) and febrile patients
~15 hours after the onset of fever (n = 3) using a multiplex bead
ELISA. Levels of IP10 were also assessed by a single-plex bead ELISA
(C, bottom right) in controls (n = 13), afebrile patients (n = 8) and
febrile patients 12 hours before, ~15 hours and ~120 hours after the
onset of fever (-12 (n = 1), ~15 (n = 3), ~120 (n = 1)). Measured
quantities are reported in Additional File 4, Table S3.
Figure 5 Flux of blood cells and serum cytokines in PFAPA.
Proposed oscillations in the abundance of blood cell populations
and inflammatory cytokines over time (x-axis: h, hours; d, days; wk,
weeks) in a typical PFAPA cycle. Pro-inflammatory cytokines in the
serum (TNFa, IL1b, IFNg, IL6) appear early after the onset of fever
[22] and are maintained (IL6) or rapidly decline (TNFa, IL1b, IFNg)a s
IFNg-induced chemokines (MIG, IP10) appear. Lymphocyte activators
IL7 and IL17 may be constitutively suppressed. The febrile period is
associated with increased neutrophils (PMN) and monocytes (Mo) as
well as decreased lymphocytes (Lym). Eosinophils (Eos) are in sparse
abundance in both febrile and afebrile intervals while thrombocytes
(Thr) rise specifically in the afebrile period. * indicates the onset of
fever.
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Page 8 of 10Additional file 3: Table S2: Complete blood count (CBC) including
differential. A table listing absolute concentrations of blood cells in
healthy and PFAPA children.
Additional file 4: Table S3: Concentration of inflammatory
mediators in serum. The concentrations of 25 inflammatory mediators
in sera from healthy children, PFAPA children in an afebrile interval or
࿄15 hours after fever commenced as determined my multiplex ELISA.
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